38 related articles for article (PubMed ID: 18173334)
1. Temozolomide and resistant glioma cells.
Kyritsis AP; Tachmazoglou F; Rao JS; Puduvalli VK
J Neurosurg; 2008 Jan; 108(1):197; author reply 197-8. PubMed ID: 18173334
[No Abstract] [Full Text] [Related]
2. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Uzzaman M; Keller G; Germano IM
J Neurosurg; 2007 Apr; 106(4):646-51. PubMed ID: 17432717
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pharmacology on DNA methylating agent temozolomide].
Hirose Y; Sano H
No Shinkei Geka; 2007 Feb; 35(2):117-29. PubMed ID: 17310751
[No Abstract] [Full Text] [Related]
4. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
[TBL] [Abstract][Full Text] [Related]
6. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Günther W; Pawlak E; Damasceno R; Arnold H; Terzis AJ
Br J Cancer; 2003 Feb; 88(3):463-9. PubMed ID: 12569392
[TBL] [Abstract][Full Text] [Related]
8. Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Trog D; Moenkemann H; Breipohl W; Schueller H; Schild H; Golubnitschaja O
Amino Acids; 2007; 32(3):373-9. PubMed ID: 17077962
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide: too early for definitive conclusions.
Brown P; Buckner J
J Clin Oncol; 2003 Oct; 21(19):3710. PubMed ID: 14512412
[No Abstract] [Full Text] [Related]
10. Delirium likely caused by interaction between phenytoin and temozolomide.
Levy M
Psychosomatics; 2007; 48(4):359-60. PubMed ID: 17600176
[No Abstract] [Full Text] [Related]
11. Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Speer TW
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1273-4. PubMed ID: 18954725
[No Abstract] [Full Text] [Related]
12. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Son MJ; Kim JS; Kim MH; Song HS; Kim JT; Kim H; Shin T; Jeon HJ; Lee DS; Park SY; Kim YJ; Kim JH; Nam DH
Int J Oncol; 2006 Jan; 28(1):53-9. PubMed ID: 16327979
[TBL] [Abstract][Full Text] [Related]
13. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Zhang H; Gao S
Int J Pharm; 2007 Feb; 329(1-2):122-8. PubMed ID: 17000068
[TBL] [Abstract][Full Text] [Related]
15. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
16. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Sahm F; Oezen I; Opitz CA; Radlwimmer B; von Deimling A; Ahrendt T; Adams S; Bode HB; Guillemin GJ; Wick W; Platten M
Cancer Res; 2013 Jun; 73(11):3225-34. PubMed ID: 23548271
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Kil WJ; Cerna D; Burgan WE; Beam K; Carter D; Steeg PS; Tofilon PJ; Camphausen K
Clin Cancer Res; 2008 Feb; 14(3):931-8. PubMed ID: 18245557
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolo[2,1-d][1,2,3,5]tetrazinones deaza analogues of temozolomide with potent antitumor activity.
Diana P; Barraja P; Lauria A; Almerico AM; Dattolo G; Cirrincione G
Farmaco; 2000 Mar; 55(3):200-1. PubMed ID: 10919082
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
Newlands ES; Stevens MF; Wedge SR; Wheelhouse RT; Brock C
Cancer Treat Rev; 1997 Jan; 23(1):35-61. PubMed ID: 9189180
[No Abstract] [Full Text] [Related]
20. Temozolomide (Temodar).
Bruce S
Clin J Oncol Nurs; 2001; 5(1):37-8. PubMed ID: 11899402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
